Travere Therapeutics, Inc. (TVTX)
50.52
+0.92
(+1.85%)
USD |
NASDAQ |
Oct 19, 13:19
Travere Therapeutics Cash from Operations (Annual) : 37.78M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 37.78M |
| December 31, 2024 | -237.48M |
| December 31, 2023 | -280.02M |
| December 31, 2022 | -186.29M |
| December 31, 2021 | -14.79M |
| December 31, 2020 | -42.74M |
| December 31, 2019 | -58.21M |
| December 31, 2018 | -24.96M |
| December 31, 2017 | 7.403M |
| December 31, 2016 | -1.596M |
| Date | Value |
|---|---|
| December 31, 2015 | -0.554M |
| December 31, 2014 | -45.85M |
| December 31, 2013 | -17.59M |
| December 31, 2012 | -2.737M |
| February 29, 2012 | |
| February 28, 2011 | -0.0007M |
| February 28, 2010 | -0.0001M |
| February 28, 2009 | -0.0202M |
| February 29, 2008 | 0.00 |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| TG Therapeutics, Inc. | -24.77M |
| BioMarin Pharmaceutical, Inc. | 827.99M |
| Vertex Pharmaceuticals, Inc. | 3.631B |
| Viridian Therapeutics, Inc. | -276.87M |
| Krystal Biotech, Inc. | 200.86M |